Skip to main content
. 2018 Nov 29;18:1182. doi: 10.1186/s12885-018-4877-5

Table 3.

Relationship between FAM19A4 methylation and clinicopathological parameters in cervical cancer

Parameters Median Methylation Methylation Rates U P*
Scores(P14P34) (%)
Age
< 48 144.14(49.89–387.46) 90.63(29/32) 445.00 0.784
≥48 140.65(62.20–466.41) 96.55(28/29)
Histology
SCC 145.37(62.54–450.44) 94.44(51/54) 144.00 0.321
AC/ASC 137.83(8.38–207.24) 85.71(6/7)
Stage
IA or IB1 153.17(67.84–387.46) 91.67(33/36) 409.00 0.548
IB2 or above 97.78(51.19–562.08) 96.00(24/25)
Size
≤4 cm 141.42(62.20–389.23) 93.88(46/49) 279.00 0.786
> 4 cm 123.54(23.42–807.25) 91.67(11/12)
Lymph node metastasis
yes 167.28(77.43–604.86) 100(10/10) 227.00 0.585
no 140.65(55.49–366.61) 92.16(47/51)

SCC squamous cell carcinoma, AC adenocarcinoma, ASC adenosquamous carcinoma

*P>0.05,Mann-Whitney U Test, methylation scores were used to calculate the statistical difference